Medicare Enrolled
Dr. Marguerite McGarvey, MD
Rheumatology · Willow Grove, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. McGarvey from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. McGarvey?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. McGarvey
Dr. Marguerite McGarvey is a rheumatology specialist in Willow Grove, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. McGarvey performed 123,280 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. McGarvey received a total of $8,908 from 33 pharmaceutical and/or device companies across 506 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McGarvey is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 11% volume in PA
$8,908 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗123,280
Medicare services
Top 11% in PA for rheumatology
Not available
Unique patients (not deduplicated)
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
32,400 | $4 | $10 |
| Tocilizumab injection (Actemra) | 30,480 | $5 | $7 |
| Denosumab injection (Prolia/Xgeva) | 20,280 | $18 | $27 |
| Romosozumab injection (Evenity) for osteoporosis | 14,280 | $8 | $20 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
9,500 | $11 | $45 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
5,600 | $34 | $75 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
3,840 | $26 | $130 |
| Privigen immune globulin injection, 500 mg An intravenous injection of Privigen, a non-lyophilized immune globulin product, administered in a 500 mg dose. |
2,000 | $37 | $110 |
| Rituximab injection, 10 mg Administration of a 10 mg dose of rituximab medication via injection. |
1,720 | $63 | $165 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,176 | $97 | $240 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
629 | $63 | $240 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
493 | $1 | $12 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
256 | $113 | $688 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
127 | $24 | $246 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
102 | $57 | $239 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
85 | $18 | $100 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
82 | $116 | $372 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
62 | $55 | $311 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
49 | $68 | $158 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
41 | $13 | $109 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
28 | $4 | $14 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
27 | $49 | $170 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
23 | $1 | $5 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
15.7% high complexity
83.2% medium
1.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,908
Total received (2018-2024)
Avg $1,273/year across 7 years
Top 32% in PA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
33
Companies
506
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,525
2023
$1,897
2022
$805
2021
$420
2020
$574
2019
$962
2018
$726
Payments by company (2024)
Amgen Inc.
$542
UCB, Inc.
$441
ABBVIE INC.
$361
Janssen Biotech, Inc.
$337
Novartis Pharmaceuticals Corporation
$315
AstraZeneca Pharmaceuticals LP
$306
Boehringer Ingelheim Pharmaceuticals, Inc.
$205
E.R. Squibb & Sons, L.L.C.
$167
Lilly USA, LLC
$147
ANI Pharmaceuticals, Inc.
$141
PFIZER INC.
$132
Genentech USA, Inc.
$103
Radius Health, Inc.
$78
GlaxoSmithKline, LLC.
$51
Kyowa Kirin, Inc.
$43
Fresenius Kabi USA, LLC
$42
Kiniksa Pharmaceuticals International, plc
$39
Sandoz Inc.
$32
SOBI, INC
$24
GENZYME CORPORATION
$20
Top 3 companies account for 38.1% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$1,827
UCB, Inc.
$1,033
Janssen Biotech, Inc.
$920
ABBVIE INC.
$742
Novartis Pharmaceuticals Corporation
$626
PFIZER INC.
$533
Genentech USA, Inc.
$394
GENZYME CORPORATION
$373
Lilly USA, LLC
$352
AstraZeneca Pharmaceuticals LP
$340
Boehringer Ingelheim Pharmaceuticals, Inc.
$229
E.R. Squibb & Sons, L.L.C.
$214
Radius Health, Inc.
$199
ANI Pharmaceuticals, Inc.
$180
Flexion Therapeutics, Inc.
$167
GlaxoSmithKline, LLC.
$140
AbbVie, Inc.
$124
AbbVie Inc.
$104
Sandoz Inc.
$46
Kyowa Kirin, Inc.
$43
Fresenius Kabi USA, LLC
$42
Aurinia Pharma U.S., Inc.
$41
Horizon Therapeutics plc
$39
Kiniksa Pharmaceuticals International, plc
$39
Sobi, Inc
$26
SOBI, INC
$24
Mallinckrodt LLC
$21
Encore Dermatology Inc.
$20
Antares Pharma, Inc.
$16
Alexion Pharmaceuticals, Inc.
$16
Kiniksa Pharmaceuticals, Ltd.
$14
MEDAC PHARMA, INC.
$14
Ironwood Pharmaceuticals, Inc
$12
Top 3 companies account for 42.4% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUZALLO · EVENITY · Enbrel · FORTEO · HUMIRA · HYRIMOZ · Humira · IDACIO · Impoyz · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · OFEV · ORENCIA · Otezla · Otrexup · PURIFIED CORTROPHIN GEL · Prolia · REMICADE · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tyenne · Tymlos · XELJANZ · Zilretta
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Rheumatologists in nearby ZIP areas
179
County median income
$111,521
Nearest hospital to ZIP centroid (approximate)
JEFFERSON ABINGTON HOSPITAL
1.5 mi
1.5 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. McGarvey is a mixed practice specialist, with above-average Medicare volume (top 11% in PA), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. McGarvey experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. McGarvey performed 32,400 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. McGarvey receive payments from pharmaceutical companies?
Yes. Dr. McGarvey received a total of $8,908 from 33 companies across 506 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. McGarvey's costs compare to other rheumatologists in Willow Grove?
Dr. McGarvey's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. McGarvey) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Willow Grove
Browse rheumatologists in Willow Grove ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in PA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in PA
Which PA rheumatologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology